VYGR — Voyager Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1640266 ·
Last close
$3.44
Market Cap
$207.85M
52W High
$4.46
52W Low
$3.26
ADV30
651,750
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,593,000 | — | -30,270,000 | -27,937,000 | 219,325,000 | 43,314,000 | 45,656,000 |
| Dec 2025 | 15,336,000 | — | -29,932,000 | -27,426,000 | 252,281,000 | 65,300,000 | 56,200,000 |
| Sep 2025 | 13,365,000 | — | -30,594,000 | -27,892,000 | 288,311,000 | 45,125,000 | 68,486,000 |
| Jun 2025 | 5,200,000 | — | -36,625,000 | -33,382,000 | 322,101,000 | 43,940,000 | 78,157,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-127,991,000
Investing CF
$92,346,000
Financing CF
$4,066,000
CapEx
$-1,952,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.98
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-473,842,000
Inventory
—
Receivables
$1,645,000
ST Investments
$98,165,000
EBIT TTM
$-127,421,000
Pretax Income TTM
$-116,516,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$36,494,000
EBITDA
$-119,943,000
Free Cash Flow
$-80,829,624
Enterprise Value
$115,437,336
Total Cash
$141,479,008
Total Debt
$34,566,000
Shares Out
60,421,287
Trailing EPS
$-1.98
Book Value
$2.88
ROE
-52.3%
ROA
-27.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 40,374,000 | -131,844,000 | -119,721,000 | 252,281,000 | 56,200,000 | — | -132,467,000 |
| Dec 2024 | 80,001,000 | -83,287,000 | -65,002,000 | 393,050,000 | 93,290,000 | — | -15,310,000 |
| Dec 2023 | 250,008,000 | 122,014,000 | 132,330,000 | 351,281,000 | 114,961,000 | — | 77,919,000 |
| Dec 2022 | 40,907,000 | -50,837,000 | -46,408,000 | 159,356,000 | 100,336,000 | — | -12,509,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.56
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLLS | Cellectis S.A. | $217.37M | $2.99 | — |
| PLX | Protalix BioTherapeutics, Inc. | $196.59M | $2.44 | — |
| DTIL | PRECISION BIOSCIENCES INC | $226.03M | $8.76 | — |
| CGEN | COMPUGEN LTD | $226.06M | $2.39 | — |
| CRBU | Caribou Biosciences, Inc. | $190.92M | $1.92 | — |
News headlines (Yahoo Finance, 1h cache)
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money
2026-07-02 13:33 · Yahoo
Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside
2026-06-30 16:34 · Yahoo
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
2026-06-29 12:01 · Yahoo
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
2026-06-11 20:01 · Yahoo
Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation
2026-06-09 10:39 · Yahoo
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
2026-06-01 12:00 · Yahoo
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs
2026-05-20 12:35 · Yahoo
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
2026-05-13 10:01 · Yahoo
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 21:55 · Yahoo
Voyager Reports First Quarter 2026 Financial and Operating Results
2026-05-07 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.